KB301 / Krystal Biotech - LARVOL DELTA

PEARL-1: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions (clinicaltrials.gov) - P1 | N=85 | Active, not recruiting | Sponsor: Krystal Biotech, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: May 2024 ➔ Oct 2024

Enrollment closed • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

PEARL-1: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions (clinicaltrials.gov) - P1 | N=85 | Recruiting | Sponsor: Krystal Biotech, Inc. | N=64 ➔ 85 | Trial completion date: May 2028 ➔ May 2029 | Trial primary completion date: Aug 2023 ➔ May 2024

Enrollment change • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

PEARL-1: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Krystal Biotech, Inc. | Active, not recruiting ➔ Recruiting | N=44 ➔ 64 | Trial completion date: Jun 2027 ➔ May 2028 | Trial primary completion date: Sep 2022 ➔ Aug 2023

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry • COL3A1

PEARL-1: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: Krystal Biotech, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2022 ➔ Jun 2027 | Trial primary completion date: Nov 2021 ➔ Sep 2022

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry • COL3A1

PEARL-1: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions (clinicaltrials.gov) - P1; N=37; Recruiting; Sponsor: Krystal Biotech, Inc.; N=22 ➔ 37

Enrollment change • CNS Disorders • Depression • Mood Disorders • Psychiatry